BiondVax Pharmaceuticals Ltd.
BVXVNASDAQHealthcare
$1.36
+$0.01(+0.74%)
Market Cap$4966625
P/E Ratio—
52W High$11.49
52W Low$0.63
BiondVax Pharmaceuticals Ltd. (BVXV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BVXV · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 11, 2023EPS Actual
$1.11
Est. -$0.91 · +222.0%
Revenue
—
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 11, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
BVXV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2023 | Nov 29, 2023 | — | — | — | — | — | — |
| ▲ Q3 FY2023 | Aug 11, 2023 | -$0.91 | $1.11 | +222.0% | — | — | — |
| — Q2 FY2023 | May 15, 2023 | — | $1.20 | — | — | — | — |
| — Q2 FY2023 | Apr 17, 2023 | — | $0.30 | — | — | — | — |
| ▼ Q4 FY2022 | Nov 30, 2022 | $0.10 | $0.06 | -40.0% | — | — | — |
| ▲ Q3 FY2022 | Aug 25, 2022 | -$1.05 | $2.10 | +300.0% | — | — | — |
| ▲ Q2 FY2022 | Jun 1, 2022 | -$1.00 | $2.00 | +300.0% | — | — | — |
| ▼ Q1 FY2022 | Mar 28, 2022 | -$0.85 | -$2.70 | -217.7% | $0.00B | — | — |
Q4 FY2023
Nov 29, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 11, 2023Beat
EPS Actual
$1.11
EPS Est.
-$0.91
EPS Surpr.
+222.0%
Revenue
—
Q2 FY2023
May 15, 2023
EPS Actual
$1.20
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
Apr 17, 2023
EPS Actual
$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 30, 2022Miss
EPS Actual
$0.06
EPS Est.
$0.10
EPS Surpr.
-40.0%
Revenue
—
Q3 FY2022
Aug 25, 2022Beat
EPS Actual
$2.10
EPS Est.
-$1.05
EPS Surpr.
+300.0%
Revenue
—
Q2 FY2022
Jun 1, 2022Beat
EPS Actual
$2.00
EPS Est.
-$1.00
EPS Surpr.
+300.0%
Revenue
—
Q1 FY2022
Mar 28, 2022Miss
EPS Actual
-$2.70
EPS Est.
-$0.85
EPS Surpr.
-217.7%
Revenue
$0.00B
No analyst estimates available for BVXV.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2023 | Aug 11, 2023 | +222.0% | $1.32 | $1.30 | -1.52% |
| — Q2 FY2023 | May 15, 2023 | — | $1.89 | $1.83 | -3.17% |
| — Q2 FY2023 | Apr 17, 2023 | — | $1.79 | $2.15 | +20.11% |
| ▼ Q4 FY2022 | Nov 30, 2022 | -40.0% | $9.55 | $9.76 | +2.20% |
| ▲ Q3 FY2022 | Aug 25, 2022 | +300.0% | $11.60 | $11.65 | +0.43% |
| ▲ Q2 FY2022 | Jun 1, 2022 | +300.0% | $13.40 | $13.10 | -2.24% |
| ▼ Q1 FY2022 | Mar 28, 2022 | -217.7% | $17.80 | $17.60 | -1.12% |
| — Q4 FY2021 | Nov 30, 2021 | — | $18.26 | $17.20 | -5.81% |
Q3 FY2023-1.52%
Report Date
Aug 11, 2023
EPS Beat/Miss
+222.0%
Price Before
$1.32
Price After
$1.30
Q2 FY2023-3.17%
Report Date
May 15, 2023
EPS Beat/Miss
—
Price Before
$1.89
Price After
$1.83
Q2 FY2023+20.11%
Report Date
Apr 17, 2023
EPS Beat/Miss
—
Price Before
$1.79
Price After
$2.15
Q4 FY2022+2.20%
Report Date
Nov 30, 2022
EPS Beat/Miss
-40.0%
Price Before
$9.55
Price After
$9.76
Q3 FY2022+0.43%
Report Date
Aug 25, 2022
EPS Beat/Miss
+300.0%
Price Before
$11.60
Price After
$11.65
Q2 FY2022-2.24%
Report Date
Jun 1, 2022
EPS Beat/Miss
+300.0%
Price Before
$13.40
Price After
$13.10
Q1 FY2022-1.12%
Report Date
Mar 28, 2022
EPS Beat/Miss
-217.7%
Price Before
$17.80
Price After
$17.60
Q4 FY2021-5.81%
Report Date
Nov 30, 2021
EPS Beat/Miss
—
Price Before
$18.26
Price After
$17.20
Avg Beat Reaction-1.11%
Avg Miss Reaction+0.54%
Beat Rate3 / 8 quarters
Largest Move+20.11% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BVXV ends December
BiondVax Pharmaceuticals Ltd. (BVXV) most recently reported earnings on August 11, 2023 for Q3 FY2023, posting EPS of $1.11 — beating the analyst consensus of $-0.91 by +222.0%. The next BVXV earnings date is expected around September 1, 2026.
Each quarter, investors track BVXV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BVXV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BVXV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BVXV earnings · 5 questionsBiondVax Pharmaceuticals Ltd.'s next earnings report is expected around September 1, 2026. BVXV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BVXV historically reports after market close (AMC).
BVXV earnings datewhen is BVXV earningsBVXV next earnings datewhen does BVXV report earningsBVXV earnings calendar
▸ Source: FMP · BiondVax Pharmaceuticals Ltd. SEC filings · US GAAP · BiondVax Pharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026